Moderna is still fending off patent challenges over the lipid nanoparticle delivery system used in the company’s COVID-19 vaccine, Spikevax.
The first World Trade Organization meeting to discuss a draft agreement to temporarily waive intellectual property rights for COVID-19 vaccines went “very well”, its chair said on May 6.
Apr 08, 2022 By Jazmine Colatriano, M.S. BioSpace Johnson & Johnson’s Janssen Pharmaceutical secured an arbitrary win regarding royalty decisions stemming from the licensing and marketing of daratumumab, an anti-CD38 monoclonal antibody treatment […]
A federal judge in Delaware tossed out a lawsuit by Roche company Genentech accusing Novartis’ Sandoz division of patent infringement. In this case, the patent was related to Genentech’s Esbriet (pirfenidone), which is used to treat idiopathic pulmonary fibrosis.
Bristol Myers Squibb Co., in a lawsuit made public on March 17, said AstraZeneca’s cancer treatment Imfinzi violates patents related to the company’s blockbuster cancer drug Opdivo.
Alnylam is suing both Moderna and Pfizer over what it claims are patent infringements related to the Cambridge, Massachusetts-based company’s biodegradable cationic lipids that it says have been foundational to the success of the mRNA-based COVID-19 vaccines developed by the two companies.
A decision made by the U.S. Court of Appeals for the Federal Circuit delivered a blow to Biogen Inc., denying a second look into the patent dispute filed against Mylan Pharmaceuticals Inc.
AstraZeneca’s rare disease arm Alexion agreed to resolve all patent disputes with Chugai Pharmaceutical regarding the prescription drug Ultomiris (ravulizumab) by signing a settlement agreement that will involve a one-time payment of $775 million.
The United States, European Union, India and South Africa reached a consensus on key elements of a long-sought intellectual property waiver for COVID-19 vaccines, according to a proposed text reviewed by Reuters.
Pharma giant AbbVie and Iceland-based Alvotech settled a case filed with the International Trade Commission. The dispute centered around Alvotech’s adalimumab biosimilar drug, which AbbVie posited had been developed through theft of trade secrets of the company’s Humira product.
